Expression of Multidrug Resistance Proteins in Rat and Human Chronic Pancreatitis

Pancreas

Volumn 28, Issue 1, 2004, Pages 45-52

  Schaarschmidt, Thomas ^a   Merkord, Jutta ^a   Adam, Ulrich ^a   Schroeder, Eike ^b   Kunert Keil, Christiane ^b   Sperker, Bernhard ^b   Drewelow, Bernd ^a   Wacke, Rainer ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

ABC transporter; Chronic pancreatitis; P glycoprotein, multidrug resistance

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PANCREAS ASSOCIATED PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; CHRONIC PANCREATITIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; CHRONIC DISEASE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PANCREAS; PANCREATITIS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0347418262     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200401000-00007     Document Type: Article

References (79)

1. Preiss R. P-glycoprotein and related transporters. Int J Clin Pharmacol Ther. 1998;36:3-8.
2. Konig J, Nies AT, Cui Y, et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta. 1999;1461:377-394.
3. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001;2:51-64.
4. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265-283.
5. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit. 2000;22:137-140.
6. Garnier-Suillerot A, Marbeuf-Gueye C, Salemo M, et al. Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr Med Chem. 2001;8:51-64.
7. Burns GP, Stein TA, Kabnick LS. Blood-pancreatic juice barrier to antibiotic excretion. Am J Surg. 1986;151:205-208.
8. Bradley EL. Antibiotics in acute pancreatitis. Current status and future directions. Am J Surg. 1989;158:472-478.
9. Buchler M, Malfertheiner P, Friess H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology. 1992;103:1902-1908.
10. Lankisch PG, Banks PA (1998) Pancreatitis. Berlin: Springer Verlag.
11. Naruse S, Kitagawa M, Ishiguro H. Molecular understanding of chronic pancreatitis: a perspective on the future. Mol Med Today. 1999;5:493-499.
12. Kleeff J, Friess H, Korc M, et al. Chronic pancreatitis: pathogenesis and molecular aspects. Ann Ital Chir. 2000;71:3-10.
13. Van Laethem JL, Deviere J. Pancreatitis and cytokines. Acta Gastroenterol Belg. 1996;59:186-187.
14. Slater S, Jalleh R, Gilbertson J, et al. Expression of heat shock proteins in chronic pancreatitis: protective or pathogenic roles? Lab Invest. 1997;76:533-545.
15. Wacke R, Kirchner A, Prall F, et al. Up-regulation of cytochrome P450 1A2, 2C9, and 2E1 in chronic pancreatitis. Pancreas. 1998;16:521-528.
16. Saurer L, Reber P, Schaffner T, et al. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. Gastroenterology. 2000;118:356-367.
17. Di Sebastiano P, di Mola FF, Di Febbo C, et al. Expression of interleukin 8 (IL-8) and substance P in human chronic pancreatitis. Gut. 2000;47:423-428.
18. Sparmann G, Behrend S, Merkord J, et al. Cytokine mRNA levels and lymphocyte infiltration in pancreatic tissue during experimental chronic pancreatitis induced by dibutyltin dichloride. Dig Dis Sci. 2001;46:1647-1656.
19. Merkord J, Jonas L, Weber H, et al. Acute interstitial pancreatitis in rats induced by dibutyltin dichloride (DBTC): pathogenesis and natural course of lesions. Pancreas. 1997;15:392-401.
20. Merkord J, Weber H, Sparmann G, et al. The course of pancreatic fibrosis induced by dibutyltin dichloride (DBTC). Ann N Y Acad Sci. 1999;880:231-237.
21. Sparmann G, Merkord J, Jaschke A, et al. Pancreatic fibrosis in experimental pancreatitis induced by dibutyltin dichloride. Gastroenterology. 1997;112:1664-1672.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
23. Sparmann G, Jaschke A, Loehr M, et al. Tissue homogenization as a key step in extracting RNA from human and rat pancreatic tissue. Biotechniques. 1997;22:408-412.
24. Vos TA, Hooiveld GJ, Koning H, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 1998;28:1637-1644.
25. Ito T, Nakano I, Koyanagi S, et al. Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy. Dig Dis Sci. 1997;42:1458-1468.
26. Siegling A, Lehmann M, Platzer C, et al. A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J Immunol Methods. 1994;177:23-28.
27. Young LC, Campling BG, Voskoglou-Nomikos T, et al. Expression of multidrug resistance protien-related genes in lung cancer: correlation with drug response. Clin Cancer Res. 1999;5:673-680.
28. Bartoli C, Baeza N, Figarella C, et al. Expression of peptide-23/pancreatitis-associated protein and Reg genes in human pituitary and adenomas: comparison with other fetal and adult human tissues. J Clin Endocrinol Metab. 1998;83:4041-4046.
29. Xu D, Arestrom I, Virtala R, et al. High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br J Haematol. 1999;106:627-633.
30. Raff T, van der Giet M, Endemann D, et al. Design and testing of □-Actin primers for RT-PCR that do not co-amplify processed pseudogenes. In: Siebert P, ed. The PCR technique: RT-PCR. Natick, MA: Eaton Publishing; 1998:161-168
31. Lu Z, Kleeff J, Shrikhande S, et al. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas. 2000;21:240-247.
32. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735-7738.
33. Pileri SA, Sabattini E, Falini B, et al. Immunohistochemical detection of the multidrug transport protein P 170 in human normal tissues and malignant lymphomas. Histopathology. 1991;19:131-140.
34. Bani D, Brandi ML, Axiotis CA, et al. Detection of P-glycoprotein on endothelial and endocrine cells of the human pancreatic islets by C 494 monoclonal antibody. Histochemistry. 1992;98:207-209.
35. Bittl A, Nap M, Jager W, et al. Immunohistochemical detection of P-glycoprotein on frozen and paraffin-embedded tissue sections of normal and malignant tissues. Anticancer Res. 1995;15:1007-1014.
36. Sugawara I, Akiyama S, Scheper RJ, et al. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett. 1997;112:23-31.
37. Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1995;1:1301-1310.
38. Miller DW, Fontain M, Kolar C, et al. The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett. 1996;107:301-306.
39. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci. 2000;3:268-280.
40. Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33:633-646.
41. Saclarides TJ, Jakate SM, Coon JS, et al. Variable expression of P-glycoprotein in normal, inflamed, and dysplastic areas in ulcerative colitis. Dis Colon Rectum. 1992;35:747-752.
42. Schrenk D, Gant TW, Preisegger KH, et al. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology. 1993;17:854-860.
43. Trauner M, Arrese M, Soroka CJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997;113:255-264.
44. Piquette-Miller M, Pak A, Kim H, et al. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res. 1998;15:706-711.
45. Hanck C, Rossol S, Singer MV. Immunological changes of mild acute pancreatitis in late-stage alcoholic chronic pancreatitis. Dig Dis Sci. 1999;44:1768-1773.
46. Hanck C, Rossol S, Hartmann A, et al. Cytokine gene expression in peripheral blood mononuclear cells reflects a systemic immune response in alcoholic chronic pancreatitis. Int J Pancreatol. 1999;26:137-145.
47. Xie MJ, Motoo Y, Su SB, et al. Expression of tumor necrosis factor-alpha, interleukin-6, and interferon-gamma in spontaneous chronic pancreatitis in the WBN/Kob rat. Pancreas. 2001;22:400-408.
48. Chapekar MS, Huggett AC, Cheng C. Dexamethasone prevents the growth inhibitory effects of recombinant tumor necrosis factor in a rat hepatoma cell line Reuber-RC-3: an association with the changes in the messenger RNA levels for multidrug resistance gene. Biochem Biophys Res Commun. 1991;181:1524-1531.
49. Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst. 1996;88:1383-1392.
50. Combates NJ, Kwon PO, Rzepka RW, et al. Involvement of the transcription factor NF-1L6 in phorbol ester induction of P-glycoprotein in U937 cells. Cell Growth Differ. 1997;8:213-219.
51. Stein U, Walther W, Laurencot CM, et al. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst. 1997;89:807-813.
52. Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol. 2001;1:189-199.
53. Lee G, Piquette-Miller M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol. 2001;79:876-884.
54. Sukhai M, Yong A, Kalitsky J, et al. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b genes. Mol Cell Biol Res Commun. 2000;4:248-256.
55. Sukhai M, Yong A, Pak A, et al. Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes. Inflamm Res. 2001;50:362-370.
56. Schoenberg MH, Buchler M, Pietrzyk C, et al. Lipid peroxidation and glutathione metabolism in chronic pancreatitis. Pancreas. 1995;10:36-43.
57. Norton ID, Apte MV, Haber PS, et al. Cytochrome P4502E1 is present in rat pancreas and is induced by chronic ethanol administration. Gut. 1998;42:426-430.
58. Szuster-Ciesielska A, Daniluk J, Kandefer-Szerszen M. Alcohol-related cirrhosis with pancreatitis. The role of oxidative stress in the progression of the disease. Arch Immunol Ther Exp (Warsz). 2001;49:139-146.
59. Ulrich AB, Schmied BM, Matsuzaki H, et al. Increased expression of glutathione S-transferase-pi in the islets of patients with primary chronic pancreatitis but not secondary chronic pancreatitis. Pancreas. 2001;22:388-394.
60. Foster JR, Idle JR, Hardwick JP, et al. Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. J Pathol. 1993;169:457-463.
61. Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem. 1997;378:787-791.
62. Burt RK, Thorgeirsson SS. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst. 1988;80:1383-1386.
63. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev. 1997;27:161-170.
64. Valverde MA, Bond TD, Hardy SP, et al. The multidrug resistance P-glycoprotein modulates cell regulatory volume decrease. EMBO J. 1996;15:4460-4468.
65. Braun M, Thevenod F. Photoaffinity labeling and purification of ZG-16p, a high-affinity dihydropyridine binding protein of rat pancreatic zymogen granule membranes that regulates a K(+)-selective conductance. Mol Pharmacol. 2000;57:308-316.
66. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695-698.
67. Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem. 1989;37:159-164.
68. Tatsuta T, Naito M, Ohara T, et al. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem. 1992;267:20383-20391.
69. Huai-Yun H, Secrest DT, Mark KS, et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun. 1998;243:816-820.
70. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A. 1999;96:3900-3905.
71. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38:69-74.
72. Schuppan D, Koda M, Bauer M, et al. Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets? Acta Gastroenterol Belg. 2000;63:366-370.
73. Kazbay K, Tarnasky PR, Hawes RH, et al. Increased transforming growth factor beta in pure pancreatic juice in pancreatitis. Pancreas. 2001;22:193-195.
74. Kim H, Seo JY, Kim KH. NF-kappaB and cytokines in pancreatic acinar cells. J Korean Med Sci. 2000;15(Suppl):S53-54.
75. Kitagawa M, Naruse S, Ishiguro H, et al. Pharmaceutical development for treating pancreatic diseases. Pancreas. 1998;16:427-431.
76. Uden S, Bilton D, Nathan L, et al. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. Aliment Pharmacol Ther. 1990;4:357-371.
77. Sugiyama M, Atomi Y, Wada N, et al. Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis. J Gastroenterol. 1997;32:374-379.
78. Su SB, Motoo Y, Xie MJ, et al. Expression of pancreatitis-associated protein (PAP) in rat spontaneous chronic pancreatitis: effect of herbal medicine Saiko-keishi-to (TJ-10). Pancreas. 1999;19:239-247.
79. Su SB, Motoo Y, Xie MJ, et al. Antifibrotic effect of the herbal medicine Saiko-keishi-to (TJ-10) on chronic pancreatitis in the WBN/Kob rat. Pancreas. 2001;22:8-17.